Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, toward patient-focused studies after Phase 1 clinical trials in healthy volunteers showed a favorable safety profile. The therapy, designed to target demyelination and protect or restore myelin integrity, may offer a differentiated, potentially first-in-class approach for multiple sclerosis treatment. Unlike existing therapies that primarily modulate the immune system, LUCID-MS aims to directly address myelin loss and neurodegeneration.
In April 2026, the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. Quantum BioPharma is strengthening operational support through a planned partnership with Allucent and engagement with neurological specialists. The full article detailing these developments can be accessed at https://ibn.fm/AUhNl.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for the treatment of neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is researching and developing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets the OTC product unbuzzd, and receives royalty payments on its sales.
The advancement of LUCID-MS into Phase 2 trials is a significant milestone for Quantum BioPharma and for the multiple sclerosis community, as it represents a potential new therapeutic approach that targets the underlying pathology of the disease rather than just its symptoms. If successful, LUCID-MS could offer a treatment option that addresses the root cause of disability progression in multiple sclerosis patients.
Forward-looking statements in this article are subject to risks and uncertainties, including those detailed in the company's SEC filings. For the latest news and updates on QNTM, visit the company’s newsroom at https://ibn.fm/QNTM. The original press release is available at https://www.newmediawire.com.
